Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy.

Dul M, Nikolic T, Stefanidou M, McAteer MA, Williams P, Mous J, Roep BO, Kochba E, Levin Y, Peakman M, Wong FS, Dayan CM, Tatovic D, Coulman SA, Birchall JC; EE-ASI Consortium.

Int J Pharm. 2019 May 1;562:303-312. doi: 10.1016/j.ijpharm.2019.03.041. Epub 2019 Mar 22.

PMID:
30910633
2.

Topical propranolol for infantile haemangiomas: a systematic review.

Price A, Rai S, Mcleod RWJ, Birchall JC, Elhassan HA.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2083-2089. doi: 10.1111/jdv.14963. Epub 2018 May 3.

PMID:
29569772
3.

Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

Moreno E, Schwartz J, Calvo A, Blanco L, Larrea E, Irache JM, Sanmartín C, Coulman SA, Soto M, Birchall JC, Espuelas S.

Int J Pharm. 2017 Nov 25;533(1):236-244. doi: 10.1016/j.ijpharm.2017.09.055. Epub 2017 Sep 28.

PMID:
28964902
4.

Accelerating Topical Anaesthesia Using Microneedles.

Davies LB, Gateley C, Holland P, Coulman SA, Birchall JC.

Skin Pharmacol Physiol. 2017;30(6):277-283. doi: 10.1159/000479530. Epub 2017 Sep 8.

5.

Development and Evaluation of Topical Gabapentin Formulations.

Martin CJ, Alcock N, Hiom S, Birchall JC.

Pharmaceutics. 2017 Aug 30;9(3). pii: E31. doi: 10.3390/pharmaceutics9030031.

6.

Minimally invasive and targeted therapeutic cell delivery to the skin using microneedle devices.

Gualeni B, Coulman SA, Shah D, Eng PF, Ashraf H, Vescovo P, Blayney GJ, Piveteau LD, Guy OJ, Birchall JC.

Br J Dermatol. 2018 Mar;178(3):731-739. doi: 10.1111/bjd.15923. Epub 2018 Feb 15.

PMID:
28865105
7.

Formulation of hydrophobic peptides for skin delivery via coated microneedles.

Zhao X, Coulman SA, Hanna SJ, Wong FS, Dayan CM, Birchall JC.

J Control Release. 2017 Nov 10;265:2-13. doi: 10.1016/j.jconrel.2017.03.015. Epub 2017 Mar 9.

PMID:
28286315
8.

Hydrodynamic gene delivery in human skin using a hollow microneedle device.

Dul M, Stefanidou M, Porta P, Serve J, O'Mahony C, Malissen B, Henri S, Levin Y, Kochba E, Wong FS, Dayan C, Coulman SA, Birchall JC.

J Control Release. 2017 Nov 10;265:120-131. doi: 10.1016/j.jconrel.2017.02.028. Epub 2017 Feb 28.

PMID:
28254630
9.

A novel liposomal drug delivery system for PMMA bone cements.

Ayre WN, Birchall JC, Evans SL, Denyer SP.

J Biomed Mater Res B Appl Biomater. 2016 Nov;104(8):1510-1524. doi: 10.1002/jbm.b.33488. Epub 2015 Aug 10.

10.

TGFβ Induces a SAMHD1-Independent Post-Entry Restriction to HIV-1 Infection of Human Epithelial Langerhans Cells.

Czubala MA, Finsterbusch K, Ivory MO, Mitchell JP, Ahmed Z, Shimauchi T, Karoo ROS, Coulman SA, Gateley C, Birchall JC, Blanchet FP, Piguet V.

J Invest Dermatol. 2016 Oct;136(10):1981-1989. doi: 10.1016/j.jid.2016.05.123. Epub 2016 Jun 29.

11.

Gene Therapy for Pyoderma Gangrenosum: Optimal Transfection Conditions and Effect of Drugs on Gene Delivery in the HaCaT Cell Line Using Cationic Liposomes.

Teagle AR, Birchall JC, Hargest R.

Skin Pharmacol Physiol. 2016;29(3):119-29. doi: 10.1159/000444859. Epub 2016 May 10.

12.

Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1.

Caucheteux SM, Mitchell JP, Ivory MO, Hirosue S, Hakobyan S, Dolton G, Ladell K, Miners K, Price DA, Kan-Mitchell J, Sewell AK, Nestle F, Moris A, Karoo RO, Birchall JC, Swartz MA, Hubbel JA, Blanchet FP, Piguet V.

J Invest Dermatol. 2016 Jun;136(6):1172-1181. doi: 10.1016/j.jid.2016.01.033. Epub 2016 Feb 16.

13.

Evaluating the sensitivity, reproducibility and flexibility of a method to test hard shell capsules intended for use in dry powder inhalers.

Chong RH, Jones BE, Díez F, Birchall JC, Coulman SA.

Int J Pharm. 2016 Mar 16;500(1-2):316-25. doi: 10.1016/j.ijpharm.2016.01.034. Epub 2016 Jan 19.

14.

Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes.

Zhao X, Birchall JC, Coulman SA, Tatovic D, Singh RK, Wen L, Wong FS, Dayan CM, Hanna SJ.

J Control Release. 2016 Feb 10;223:178-187. doi: 10.1016/j.jconrel.2015.12.040. Epub 2015 Dec 29.

15.

Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin.

Ali MA, Thrower SL, Hanna SJ, Coulman SA, Birchall JC, Wong FS, Dayan CM, Tatovic D.

Immunology. 2015 Nov;146(3):411-22. doi: 10.1111/imm.12518. Epub 2015 Sep 13.

16.

Early Dengue Virus Infection in Human Skin: A Cycle of Inflammation and Infectivity.

Ivory MO, Birchall JC, Piguet V.

J Invest Dermatol. 2015 Jul;135(7):1711-1712. doi: 10.1038/jid.2014.544.

17.

Dynamic visualization of dendritic cell-antigen interactions in the skin following transcutaneous immunization.

Rattanapak T, Birchall JC, Young K, Kubo A, Fujimori S, Ishii M, Hook S.

PLoS One. 2014 Feb 24;9(2):e89503. doi: 10.1371/journal.pone.0089503. eCollection 2014.

18.

The development of a sensitive methodology to characterise hard shell capsule puncture by dry powder inhaler pins.

Torrisi BM, Birchall JC, Jones BE, Díez F, Coulman SA.

Int J Pharm. 2013 Nov 18;456(2):545-52. doi: 10.1016/j.ijpharm.2013.08.011. Epub 2013 Aug 18.

PMID:
23965433
19.

Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.

Pearton M, Pirri D, Kang SM, Compans RW, Birchall JC.

Adv Healthc Mater. 2013 Oct;2(10):1401-10. doi: 10.1002/adhm.201300006. Epub 2013 Apr 8.

20.

Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.

Chong RH, Gonzalez-Gonzalez E, Lara MF, Speaker TJ, Contag CH, Kaspar RL, Coulman SA, Hargest R, Birchall JC.

J Control Release. 2013 Mar 28;166(3):211-9. doi: 10.1016/j.jconrel.2012.12.030. Epub 2013 Jan 8.

21.

An anisotropic, hyperelastic model for skin: experimental measurements, finite element modelling and identification of parameters for human and murine skin.

Groves RB, Coulman SA, Birchall JC, Evans SL.

J Mech Behav Biomed Mater. 2013 Feb;18:167-80. doi: 10.1016/j.jmbbm.2012.10.021. Epub 2012 Nov 19.

PMID:
23274398
22.

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin.

Torrisi BM, Zarnitsyn V, Prausnitz MR, Anstey A, Gateley C, Birchall JC, Coulman SA.

J Control Release. 2013 Jan 28;165(2):146-52. doi: 10.1016/j.jconrel.2012.11.010. Epub 2012 Nov 23.

23.

Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation.

Yildiz A, John E, Özsoy Y, Araman A, Birchall JC, Broadley KJ, Gumbleton M.

J Control Release. 2012 Sep 10;162(2):456-63. doi: 10.1016/j.jconrel.2012.07.008. Epub 2012 Jul 16.

PMID:
22800577
24.

Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion and gene expression.

Pearton M, Saller V, Coulman SA, Gateley C, Anstey AV, Zarnitsyn V, Birchall JC.

J Control Release. 2012 Jun 28;160(3):561-9. doi: 10.1016/j.jconrel.2012.04.005. Epub 2012 Apr 10.

25.

Visualization of plasmid delivery to keratinocytes in mouse and human epidermis.

González-González E, Kim YC, Speaker TJ, Hickerson RP, Spitler R, Birchall JC, Lara MF, Hu RH, Liang Y, Kirkiles-Smith N, Prausnitz MR, Milstone LM, Contag CH, Kaspar RL.

Sci Rep. 2011;1:158. doi: 10.1038/srep00158. Epub 2011 Nov 15.

26.

Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications.

Martin CJ, Allender CJ, Brain KR, Morrissey A, Birchall JC.

J Control Release. 2012 Feb 28;158(1):93-101. doi: 10.1016/j.jconrel.2011.10.024. Epub 2011 Oct 29.

PMID:
22063007
27.

Quantifying the mechanical properties of human skin to optimise future microneedle device design.

Groves RB, Coulman SA, Birchall JC, Evans SL.

Comput Methods Biomech Biomed Engin. 2012;15(1):73-82. doi: 10.1080/10255842.2011.596481. Epub 2011 Jul 12.

PMID:
21749225
28.

Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.

Pearton M, Kang SM, Song JM, Anstey AV, Ivory M, Compans RW, Birchall JC.

PLoS One. 2010 Aug 25;5(8):e12410. doi: 10.1371/journal.pone.0012410. Erratum in: PLoS One. 2010;5(11). doi: 10.1371/annotation/00a3b22e-36a9-4d51-89e5-1e6561e7a1e9.

29.

Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin.

Pearton M, Kang SM, Song JM, Kim YC, Quan FS, Anstey A, Ivory M, Prausnitz MR, Compans RW, Birchall JC.

Vaccine. 2010 Aug 23;28(37):6104-13. doi: 10.1016/j.vaccine.2010.05.055. Epub 2010 Jun 8.

30.

Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.

Song JM, Kim YC, Lipatov AS, Pearton M, Davis CT, Yoo DG, Park KM, Chen LM, Quan FS, Birchall JC, Donis RO, Prausnitz MR, Compans RW, Kang SM.

Clin Vaccine Immunol. 2010 Sep;17(9):1381-9. doi: 10.1128/CVI.00100-10. Epub 2010 Jul 14.

31.

In vivo, in situ imaging of microneedle insertion into the skin of human volunteers using optical coherence tomography.

Coulman SA, Birchall JC, Alex A, Pearton M, Hofer B, O'Mahony C, Drexler W, Považay B.

Pharm Res. 2011 Jan;28(1):66-81. doi: 10.1007/s11095-010-0167-x. Epub 2010 May 13.

PMID:
20464461
32.

Microneedles in clinical practice--an exploratory study into the opinions of healthcare professionals and the public.

Birchall JC, Clemo R, Anstey A, John DN.

Pharm Res. 2011 Jan;28(1):95-106. doi: 10.1007/s11095-010-0101-2. Epub 2010 Mar 18.

PMID:
20238152
33.

In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler.

Bains BK, Birchall JC, Toon R, Taylor G.

J Pharm Sci. 2010 Jul;99(7):3089-99. doi: 10.1002/jps.22085.

PMID:
20166201
34.

Microneedle mediated delivery of nanoparticles into human skin.

Coulman SA, Anstey A, Gateley C, Morrissey A, McLoughlin P, Allender C, Birchall JC.

Int J Pharm. 2009 Jan 21;366(1-2):190-200. doi: 10.1016/j.ijpharm.2008.08.040. Epub 2008 Sep 4.

PMID:
18812218
35.

A comparison of the puncturing properties of gelatin and hypromellose capsules for use in dry powder inhalers.

Birchall JC, Jones BE, Morrissey A, Jones BE.

Drug Dev Ind Pharm. 2008 Aug;34(8):870-6. doi: 10.1080/03639040801928903 . Erratum in: Drug Dev Ind Pharm. 2008 Sep;34(9):1011.

PMID:
18686093
36.

Clinical administration of microneedles: skin puncture, pain and sensation.

Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, Morrissey A, Birchall JC.

Biomed Microdevices. 2009 Feb;11(1):35-47. doi: 10.1007/s10544-008-9208-1.

PMID:
18663579
37.

Nuclear localisation and pDNA condensation in non-viral gene delivery.

Collins E, Birchall JC, Williams JL, Gumbleton M.

J Gene Med. 2007 Apr;9(4):265-74.

PMID:
17397103
38.

Minimally invasive cutaneous delivery of macromolecules and plasmid DNA via microneedles.

Coulman SA, Barrow D, Anstey A, Gateley C, Morrissey A, Wilke N, Allender C, Brain K, Birchall JC.

Curr Drug Deliv. 2006 Jan;3(1):65-75.

PMID:
16472095
39.

Microneedle array technology: the time is right but is the science ready?

Birchall JC.

Expert Rev Med Devices. 2006 Jan;3(1):1-4. Review. No abstract available.

PMID:
16359245
40.

The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy.

Li HY, Seville PC, Williamson IJ, Birchall JC.

J Gene Med. 2005 Aug;7(8):1035-43.

PMID:
15756712
41.

The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy.

Li HY, Seville PC, Williamson IJ, Birchall JC.

J Gene Med. 2005 Mar;7(3):343-53.

PMID:
15515142
42.

Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy.

Li HY, Neill H, Innocent R, Seville P, Williamson I, Birchall JC.

J Drug Target. 2003 Aug;11(7):425-32.

PMID:
15203931
43.

Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying.

Seville PC, Kellaway IW, Birchall JC.

J Gene Med. 2002 Jul-Aug;4(4):428-37.

PMID:
12124985
44.

Statistical modelling of the formulation variables in non-viral gene delivery systems.

Birchall JC, Waterworth CA, Luscombe C, Parkins DA, Gumbleton M.

J Drug Target. 2001 Jun;9(3):169-84.

PMID:
11697203
45.

Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes.

Birchall JC, Marichal C, Campbell L, Alwan A, Hadgraft J, Gumbleton M.

Int J Pharm. 2000 Mar 20;197(1-2):233-8.

PMID:
10704810
46.

Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes.

Birchall JC, Kellaway IW, Gumbleton M.

Int J Pharm. 2000 Mar 20;197(1-2):221-31.

PMID:
10704809
47.

Physico-chemical characterisation and transfection efficiency of lipid-based gene delivery complexes.

Birchall JC, Kellaway IW, Mills SN.

Int J Pharm. 1999 Jun 25;183(2):195-207.

PMID:
10361170
48.

Production of null mutants in the major intestinal esterase gene (ges-1) of the nematode Caenorhabditis elegans.

McGhee JD, Birchall JC, Chung MA, Cottrell DA, Edgar LG, Svendsen PC, Ferrari DC.

Genetics. 1990 Jul;125(3):505-14.

Supplemental Content

Loading ...
Support Center